Mi az ára Poseida Therapeutics, Inc. (PSTX)

Poseida Therapeutics, Inc. (PSTX) ára $9.50

Mi a Poseida Therapeutics, Inc. (PSTX piaci tőkésítése)

Poseida Therapeutics, Inc. piaci tőkésítése (PSTX) $819.52M

Poseida Therapeutics, Inc. (PSTX) Forgalomban Lévő Részvények

Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.

Év	Kintlévő részvények	Változtassa meg
2026 (TTM)	97.16M	7.73%
2023	90.19M	25.41%
2022	71.91M	15.66%
2021	62.18M	6.47%
2020	58.40M	46.98%
2019	39.73M	10.59%
2018	35.93M	-9.57%
2017	39.73M	-33.01%
2016	59.32M	0.00%

Év

Kintlévő részvények

Változtassa meg

2026 (TTM)

97.16M

7.73%

2023

90.19M

25.41%

2022

71.91M

15.66%

2021

62.18M

6.47%

2020

58.40M

46.98%

2019

39.73M

10.59%

2018

35.93M

-9.57%

2017

39.73M

-33.01%

2016

59.32M

0.00%

Vállalat	Kintlévő részvények	Különbség	Ország
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	161.32%	US
Argenx SE ARGX.US	62.19M	-36.00%	NL
CSL Limited CSL.AX	478.91M	392.91%	AU
Moderna, Inc. MRNA.US	396.00M	307.57%	US
Lonza Group AG LONN.SW	-	-	CH

Vállalat

Kintlévő részvények

Különbség

Ország